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ABSTRACT: Objective: To analyse the recent findings regarding 
programmed-death ligand 1(PD-L1) expression on tumor 
infiltrating immune cells in NSCLC and its potential role as a 
predictive biomarker for clinical outcomes and for successful 
PD-1/PD-L1 blocking immunotherapy. Methods: 5 databases 
were accessed for search: PubMed, Web of Science, Scopus, 
Lilacs, and Clinical Trials.gov. Articles were selected if written 
in English, Portuguese or Spanish and if available via institutional 
access. Results: 15 articles were selected. PD-L1 expression was 
found to be related to the presence of immature DCs and had 
also constitutive expression on fibroblasts derived from NSCLC 
specimens. PD-L1 expression in tumor infiltrating immune cells 
was observed to be correlated with overall survival benefit and 
improved tumor response after atezolizumab therapy. A significant 
correlation between PD-L1 expression in peripheral T cells 
and clinical outcomes was also detected, besides the finding of 
significant correlation between an increased PD-L1 expression 
and clinical benefits in anti-PD-1 therapy. Discussion: Preliminary 
observations showed that PD-L1 expression in immune cells is 
related to an immunosuppressive milieu in NSCLC and to clinical 
benefits of immunotherapy.
Keywords: Immunotherapy; Carcinoma, non-small-cell lung; 
Antigens, CD274; Biomarkers.
RESUMO: Objetivo: Analisar a literatura científica para a 
expressão de PD-L1 no infiltrado de células imunes de tumores 
do tipo CPCNP, além de seu potencial uso como biomarcador 
preditivo de desfechos clínicos e de resposta à imunoterapia com 
drogas anti PD-1 e anti PD-L1. Métodos: 5 bases de dados foram 
consultadas para buscas (PubMed, Web of Science, Scopus, Lilacs 
e Clinical Trials.gov.). Artigos foram incluídos se pertinentes, 
disponíveis através de acesso institucional e se escritos em 
Português, Inglês ou Espanhol. Não houve restrição na seleção 
quanto tipo de estudo ou ano de publicação. Resultados: 15 
artigos foram selecionados.  Foi observado relação entre o nível de 
expressão de PD-L1 e a presença de células dendríticas imaturas, 
além de expressão constitutiva da molécula em fibroblastos de 
pacientes com CPCNP. A expressão de PD-L1 nas células imunes 
infiltradas correlacionou-se com sobrevida aumentada e resposta 
tumoral melhor após terapia com atezolizumab, além de benefícios 
clínicos na terapia anti-PD-1. Outros artigos demonstram 
correlação significativa entre a expressão de PD-L1 em linfócitos 
T periféricos e desfechos clínicos. Discussão: Observações 
preliminares demonstraram que a expressão de PD-L1 nas células 
imunes estão relacionadas ao sucesso clínico da imunoterapia e 
ao microambiente imunossupressor visto no CPCNP.
Descritores: Imunoterapia; Carcinoma pulmonar de células não 
pequenas; Antígenos CD274; Biomarcadores.
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INTRODUCTION
Non-Small Cell Lung Cancer (NSCLC) accounts for approximately 85%1,2 of all lung cancer 
cases worldwide and is considered nowadays the most 
important cause of cancer-related deaths around the globe3.
It is worth noting that oncologic treatment with a 
wide range of conventional therapies has been available 
and adopted for decades2, but overall prognosis of NSCLC 
still remains unfavorable. In fact, the development of new 
and alternative therapies for NSCLC was reinforced lately 
by the promise of significant survival benefits for patients 
and the prospects of improved management in treatment 
toxicities4.
Anti-tumor interventions based on immune system 
responses are not an innovative anti-cancer strategy, with 
studies dating back to mid -1970s5. Indeed, the accumulated 
comprehension of immune system’s ability to fight cancer 
culminated more recently in the development of new 
immunotherapeutic agents, as therapeutic vaccines and 
immune checkpoint inhibitors4,6.
Immune checkpoints, elected as object of great 
interest in last years, consist of various signaling pathways 
responsible for immunomodulation effects. Under 
physiological conditions, they are essential for providing 
self-tolerance and avoiding tissue damage, while in tumors 
they contribute to immune editing and tolerance7.
The axis PD-1/PD-L1 is an important mechanism 
for inducing immune escape, leading to anergy and 
exhaustion of T-cells. PD-L1 is found to be overexpressed 
in several types of cancer, including NSCLC7.
Examples of immunotherapy concerning 
checkpoint inhibitors are monoclonal antibodies that 
block the interaction of PD-1 on lymphocytes and PD-L1 
on Antigen Presenting Cells (APCs) and tumor cells. They 
have already been applicable to melanoma, Hodgkin´s 
lymphoma, bladder cancer and non-small cell lung cancer 
(NSCLC), among others8. 
Nonetheless, not all patients with NSCLC will have 
significant benefits from immune checkpoint blocking 
drugs. Determining predictive biomarkers related to 
tumor response and clinical efficacy of these drugs is 
therefore essential to select those best candidates to 
immunotherapy.
The expression of PD-L1 in tumor cells has been 
largely considered as a potential predictive biomarker 
for clinical outcomes by many authors9,10,11. The same 
correlation between PD-L1 expression on tumor 
infiltrating immune cells and clinical outcomes has been, 
however, less frequently explored in scientific literacy.
In fact, studies approaching the issue resulted in 
the suggestion that increased expression of this molecule 
in tumor microenvironment could be possibly related to 
better clinical responses12,13,14.
Therefore, we intend to review here the current 
understanding of PD-L1 expression on infiltrating immune 
cells in NSCLC, as well its potential as a predictive 
biomarker for clinical outcomes and for PD-1/PD-L1 
immunotherapy response.
METHODS
Five databases were selected for search (PubMed, 
Web of Science, Clinical Trials.gov, Lilacs and Scopus).
To be included, articles should have adequate 
content, i.e., the expression and role of the molecule PD-L1 
in the microenvironment (stroma and/or immune cells) in 
the context of non-small-cell lung cancer.
Criteria for exclusion were:
1. The language of articles (exclusion occurred if 
articles were not written in Portuguese, Spanish or English);
2. The availability of access;
3. Presence of abstracts/titles reporting PD-
L1 expression in infection, other types of cancer or 
autoimmunity as main theme.
There was no restriction about the type of articles. 
Papers reporting experimental models should describe the 
cell lines used in tests. References were manually checked.
Search Strategy
Two search strategies for the retrieval of manuscripts 
were designed: one for Clinical Trials.gov and another one 
for the others 4 databases.
In Clinical Trials.gov, searches were made with the 
following combined terms:
- ‘’MPDL3280A’’ and ‘’Non Small Cell Lung 
Cancer’’;
- ‘’MEDI4736’’ and ‘’ Non Small Cell Lung 
Cancer’’; 
- ‘’MSB0010718C’’ and ‘’Non Small Cell Lung 
Cancer’’.
On the remaining databases, terms were combined 
as below to guarantee an adequate retrieval of articles. 
Controlled vocabulary was also adopted, specially as 
MeSH terms.
- PD-L1 and tumor infiltrating and biomarker
- PD-L1and tumor microenvironment AND 
biomarker
- PD-L1and tumor infiltrating and immunotherapy
- PD-L1and tumor microenvironment AND 
immunotherapy
- PD-L1 and myeloid cells and non small cell lung 
cancer
- PD-L1 and dendritic cells and non small cell lung 
cancer
- PD-L1 and macrophages and non small cell lung 
cancer
- PD-L1 and lymphocytes and non small cell lung 
cancer
- antigens, cd274 [mesh]) and myeloid cells [mesh]
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- antigens, cd274 [mesh]) and dendritic cells [mesh]
- antigens, cd274”[mesh]) and carcinoma, 
non-small-cell  lung [mesh]) and tumor 
microenvironment [mesh] 
- tumor microenvironment [mesh]) and antigens, 
cd274 [mesh] 
- lymphocytes, tumor-infiltrating [mesh]) and 
antigens, cd274 [mesh]) and carcinoma, non-
small-cell lung [mesh]
RESULTS
Fifteen articles were selected after search, as 
described in Table 1.
Papers were then examined according to the type 
of cells studied, experimental designs and assessment 
methodology for PD-L1 expression (Table 2).
These points usually vary in scientific reports 
concerning PD-L1 expression, and have already been 
considered, among other factors, as obstacles for use of this 
molecule as a predictive biomarker in clinical outcomes14.
For systematization, articles were also clustered 
in 3 different groups and graphically organized (Table 2).
Table 1. Description of number of articles retrieved and selected 
for each database
Data Base Number of articles retrieved in search




Web of Science 432 7
Lilacs 0 0
Clinical Trials.Gov 56 0
Articles retrieved after 
manual search 1 1
Full amount of articles 
selected for review after 
removal of duplicates and 
correction
15
Table 2. Main findings of the articles included in the review
 
PD-L1 expression in cells culture 
and experimental models
PD-L1 expression on tumor infiltrating 
cells extracted from oncologic patients
Clinical implications of PD-L1 expression as prognostic 
and predictive biomarker
Articles 
Deng et al.15 Nazareth et al.20 Herbst et al.13
Chen et al.16 Mu et al.21 Müller et al.25
Noman et al.17 Perrot et al.22 Fehrenbacher et al.26
Ni et al.18 Ilie et al.23 Taube et al.27
Akbay et al.19 Yang et al.24 Meniawy et al.28
Types of cells 
studied
Myeloid-derived suppressor cells, 
DCs and macrophages15-17
Fibroblasts derived from NSCLC 
biopsies20 Macrophages, DC and lymphocytes
13
Murine DC18 TIDC (tumor-infiltrating dendritic cell)21,22 Tumor-infiltrating myeloid cells25
Macrophages infiltrated in tumor and 
associated hematopoietic cells19
Tumor-infiltrating immune cells (no 
further specification)23,24
Tumor-infiltrating immune cells (no further specification)26
  Tumor-infiltrating lymphocytes, histiocyte/macrophages and native stroma27
  Peripheral blood T lymphocytes28
Experimental 
design of the study 
Injection of varied tumor cells lines 
in murine model followed by cells 
collection and molecular analysis of 
PD-L1 expression15-17
Tumor associated fibroblasts and tumor 
associated T cells isolation with following 
growth of fibroblasts20
Pretreatment tumor specimens collected for PD-L1 study, 
followed by correlation with clinical outcomes13,27
Co-incubation of labeled Lewis lung 
cancer cells, fibroblasts and DCs, 
followed by analysis of TGF-β and 
PD-L1 expression on DCs18
Biopsy sections deparaffinized and 
analysed for PD-L1 expression on tumor 
and TIDC, as well as for maturation status 
of these immune cells21
Patients assessed for PD-L1 tumor-infiltrating immune cell 
status and randomly allocated to receive atezolizumab or 
docetaxel. Clinical following until death of patients26
Microenvironment analysis of EGFR 
mutated tumor19
Study of TIDC obtained from pulmonary 
mononuclear cell suspension22
Retrospective comparison of PD-L1 expression on stroma 
and tumor cells in primary lesions versus metastatic 
lesions25
 PD-L1 expression on surgical tissue sections versus previous lung biopsies23
Collection of blood samples before and after therapy with 
EGFR inhibitors, followed by correlation between PD-L1 
expression and clinical outcomes28
 
PD-L1 expression on immune and tumor 






Flow cytometry15-19 Flow cytometry20,22 IHC13,25-27
IHC19
Immunofluorescence staining and 
confocal microscopy for PD-L1 
expression in DC21
Flow cytometry28
 IHC23,24  
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Articles approaching PD-L1 expression in cells 
culture and experimental models composed the first group. 
Here, Dendritic Cells (DCs) and myeloid cells were the 
cells most frequently used for study, as well as flow 
cytometry for assessment of PD-L1 expression. One of 
the articles adopted both immunohistochemistry and flow 
cytometry for PD-L1 assessment19.
Experimental designs chosen for studies presented 
great variability, including injection of varied tumor cells 
lines in mice followed by immune cells collection and the 
establishment of  an in vitro18 and an in vivo19 lung cancer 
microenvironment.
The main results concerning PD-L1 expression 
showed increased presence on DCs and tumor cells after 
tumor radiation15, on aged mice when compared to young 
animals16, on tumor infiltrating Myeloid Derived Supressor 
Cells (MDSCs), macrophages and DC of tumor cultured 
under hypoxia17 and TGF-β18 and on hematopoietic cells 
associated to EFGR mutated tumors19.
Articles approaching PD-L1 expression on tumor 
infiltrating cells extracted from oncologic patients 
composed the second group. Here, tumor-infiltrating 
dendritic cells were the cell type most frequently used for 
study. Fibroblasts, considered as important components 
of tumor stroma, were object of study in just one of 
the articles selected for this review20. Flow cytometry 
and immunohistochemistry were equally used for 
assessment of PD-L1 expression, with authors electing 
immunofluorescence staining and confocal microscopy for 
PD-L1 expression in one of the articles21.
Results of this section of works explored  the finding 
of immature dendritic infiltrating DCs in tumoral and 
peritumoral tissues, with increased expression of PD-L1 
when compared to mature DCs21,22. It was also demonstrated 
the constitutive expression of PD-L1 on fibroblasts derived 
from NSCLC specimens, as well the up-regulation of PD-
L1 in these stroma cells after IFN-γ treatment20.
In a retrospective study, Ilie et al.23 presented an 
overall discordance rate of 48% between PD-L1 expression 
on surgical resected and matched biopsy specimens of 
patients diagnosed with NSCLC and not treated with 
Radiotherapy (RT) or Chemotherapy (CT). For the authors, 
75% of the discordant cases could be credited to PD-L1 
positivity of immune infiltrate cells in resection specimens 
and previous negative results for ICs on diagnostic 
biopsies23.
Articles approaching clinical implications of PD-
L1 expression as prognostic and predictive biomarker 
composed the third and last group. Here, diverse types of 
immune cells were used for study, without any clear trend. 
All researchers, with exception in one paper28, worked with 
IHC to assess PD-L1 expression.
Results of this last section included:
•	Statistical significant association of response to 
MPDL3280A treatment and tumor-infiltrating 
immune cell PD-L1 expression in NSCLC13;
•	No significant difference in PD-L1 expression on 
tumor or myeloid cells when comparing primary 
tumors and corresponding metastases25;
•	Correlation of overall survival benefit from 
atezolizumab therapy  with PD-L1 expression 
on tumor cells, tumor infiltrating immune cells, 
or both26; 
•	No statistical significance with objective clinical 
response (p=0.14), but significant correlation 
with clinical benefit after anti PD-1 therapy.
(p=0.038)27;
•	Significant correlation between PD-L1 expression 
on peripheral T cells and clinical outcomes in 
EGFR-TKI-treated NSCLC28.
DISCUSSION
PD-L1 expression in tumor infiltrating immune cells 
was considered in a reduced number of articles. In fact, 
questions addressing its clinical implication or specifically 
its expression in the context of NSCLC also seemed slightly 
explored in literature, indicating a potential direction for 
future researches.
Another important aspect to be considered was 
the heterogeneity between articles selected. There was no 
consensus about the type of cells used, about experimental 
design of study or methodological assessment for PD-L1 
expression. Articles containing experimental model worked 
with different cell lines, with no correlation to NSCLC seen 
in patients. The development of cells cultures resembling 
the tumor microenvironment was also a difficult task.
Articles approaching clinical implications had also 
registered different experimental designs in each study, 
with different results obtained in this section. PD-L1 
expression was, however, only implicated with clinical 
benefits or prognostic factor in interventional studies with 
therapies directed to immune checkpoints. We did not find 
any article approaching the relationship between PD-L1 
expression and clinical outcomes derived from natural 
history or traditional oncologic treatments. Our results do 
not support an increased risk for metastasis occurrence in 
PD-L1 positive patients.
The finding of immature infiltrating DCs was 
frequently pointed in articles selected for this review. 
This observation is consistent with the described PD-L1 
function on immune system, and can become a future point 
of interest and clinical intervention.
In fact, the data here collected point to the 
need for further investigations, since that preliminary 
observations showed PD-L1 expression on immune cells 
related to clinical success in immunotherapy and to an 
immunosuppressive milieu in the context of NSCLC.
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